Skip to main content

November 3, 2015

– Published

Researchers in Stockholm, Uppsala, Linköping and Lund, including Prof. Carl Borrebaeck of the Dept. of Immunotechnology today argued in favor of more increased funding for development of personalized medicine in Sweden